5th mRNA Process Development & CMC Summit

Key questions include:

• Are current circRNA purification strategies fundamentally overcomplicated – and where can we simplify without compromising quality?
• How do you balance purity, yield, and scalability when designing purification processes for clinical and commercial manufacturing?
• What will define a “fit-for-purpose” purification platform for circRNA as the field moves toward first-in-human and beyond?

• Exploring how enzyme-free purification strategies can overcome key manufacturing bottlenecks in circular RNA development while improving scalability, recovery, and product purity
• Discussing the commercial and CMC implications of reducing purification complexity, lowering cost-per-dose, and minimizing supply chain dependency across clinical-tocommercial manufacturing
• Sharing early regulatory, process development, and scale-up considerations from advancing circular RNA therapeutics toward first-in-human studies